Article

Accommodating IOL yields excellent visual results for myopia, hyperopia

An accommodating IOL provides excellent visual results in patients with hyperopia or myopia.

Key Points

Dr. Carter, in private practice in Dallas, undertook a study of 1,978 eyes to determine whether the lens works in patients who have extraordinarily long or short axial lengths and whether it works with very low- and very high-power lens implant powers, considering the proposed mechanism of action of the lens implant. The accommodating lens comes in a range of powers-from 4 to 33 D-that is larger than that of multifocal lens implants, he said.

It is important to note that these results are monocular outcomes only, Dr. Carter said, adding that some deliberate planned myopic targeted refractive outcomes were included in these data.

"When the [lens] was evaluated in hyperopic patients between plano and +3.0 D, the UCDVA, the UCIVA, and the UCNVA were compared with the 20/25, 20/30, and 20/40 metrics," he said. Eighty-five percent of the hyperopic patients had UCDVA of 20/40 or better, 97% had 20/40 UCIVA or better, and 92% had 20/40 UCNVA or better, he added, and 65% of patients had 20/25 UCDVA or better, 92% had 20/25 UCIVA or better, and 64% had 20/25 UCNVA or better.

In the group of patients with very high hyperopia, he said, the numbers "dramatically improved," with 78% of patients having UCDVA of 20/25 or better, 96% having UCIVA of 20/25 or better, and 75% having UCNVA of 20/25 or better. Ninety-one percent had 20/40 or better at distance, 100% had UCIVA of 20/40 or better, and 94% had UCNVA of 20/40 or better.

Statistical improvement in the myopic eyes was less than that seen in hyperopic eyes; nonetheless, Dr. Carter described the results as "impressive." Fifty-one percent of patients had 20/25 UCDVA or better, 91% had UCIVA of 20/25 or better, and 62% had UCNVA of 20/25 or better. Eighty-one percent had 20/40 or better UCDVA, 97% had 20/40 or better UCIVA, and 88% had 20/40 or better UCNVA. The UCDVA data were adversely affected by planned myopic refractive outcome targets, he said.

"The hyperopic patients did slightly better than the myopic patients, especially in the near and intermediate visual acuity levels. This occurred despite slightly hyperopic outcomes," Dr. Carter said. "The normal target for the accommodating [lens] is not hyperopic but typically slightly myopic."

No lenses were explanted in either group for any reason, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.